Show simple item record

dc.contributor.authorCollet, Jean-Philippe
dc.contributor.authorMontalescot, Gilles
dc.contributor.authorAgnelli, Giancarlo
dc.contributor.authorVan de Werf, Frans
dc.contributor.authorGurfinkel, Enrique P.
dc.contributor.authorLópez-Sendón, José
dc.contributor.authorLaufenberg, Christopher V.
dc.contributor.authorKlutman, Martin
dc.contributor.authorGowda, Neelam
dc.contributor.authorGulba, Dietrich C.
dc.contributor.authorGRACE Investigators
dc.date2022-08-11T08:08:08.000
dc.date.accessioned2022-08-23T15:44:07Z
dc.date.available2022-08-23T15:44:07Z
dc.date.issued2005-11-04
dc.date.submitted2011-09-23
dc.identifier.citationEur Heart J. 2005 Nov;26(21):2285-93. Epub 2005 Jun 2. <a href="http://dx.doi.org/10.1093/eurheartj/ehi337">Link to article on publisher's site</a>
dc.identifier.issn0195-668X (Linking)
dc.identifier.doi10.1093/eurheartj/ehi337
dc.identifier.pmid15932908
dc.identifier.urihttp://hdl.handle.net/20.500.14038/27244
dc.description.abstractAIMS: To determine whether low-molecular-weight heparin (LMWH)+glycoprotein (GP) IIb/IIIa inhibitors provide greater benefit than unfractionated heparin (UFH)+GP IIb/IIIa inhibitors, irrespective of renal status. METHODS AND RESULTS: Patients in the Global Registry of Acute Coronary Events (GRACE) were divided into three groups according to creatinine clearance (CrCl): normal renal function (CrCl >60 mL/min), moderate renal dysfunction (30 CONCLUSION: In patients with renal dysfunction and non-ST-segment elevation ACS, bleeding complications are more frequent and outcomes appear worse in individuals treated with UFH compared with LMWH. Combination therapy with LMWH and GP IIb/IIIa inhibitors appears to be better tolerated than with UFH and GP IIb/IIIa inhibitors.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=15932908&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttp://dx.doi.org/10.1093/eurheartj/ehi337
dc.subjectAcute Disease
dc.subjectAdolescent
dc.subjectAdult
dc.subjectAged
dc.subjectAged, 80 and over
dc.subjectAnticoagulants
dc.subjectCoronary Disease
dc.subjectDrug Therapy, Combination
dc.subjectFemale
dc.subjectHemorrhage
dc.subjectHeparin, Low-Molecular-Weight
dc.subjectHumans
dc.subjectKidney Diseases
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectPlatelet Glycoprotein GPIIb-IIIa Complex
dc.subjectProspective Studies
dc.subjectStatistics as Topic
dc.subjectSyndrome
dc.subjectTreatment Outcome
dc.subjectHealth Services Research
dc.titleNon-ST-segment elevation acute coronary syndrome in patients with renal dysfunction: benefit of low-molecular-weight heparin alone or with glycoprotein IIb/IIIa inhibitors on outcomes. The Global Registry of Acute Coronary Events
dc.typeArticle
dc.source.journaltitleEuropean heart journal
dc.source.volume26
dc.source.issue21
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/cor_grace/63
dc.identifier.contextkey2254984
html.description.abstract<p><h4>AIMS:</h4></p> <p>To determine whether low-molecular-weight heparin (LMWH)+glycoprotein (GP) IIb/IIIa inhibitors provide greater benefit than unfractionated heparin (UFH)+GP IIb/IIIa inhibitors, irrespective of renal status. <h4>METHODS AND RESULTS:</h4></p> <p>Patients in the Global Registry of Acute Coronary Events (GRACE) were divided into three groups according to creatinine clearance (CrCl): normal renal function (CrCl >60 mL/min), moderate renal dysfunction (30 <h4>CONCLUSION:</h4></p> <p>In patients with renal dysfunction and non-ST-segment elevation ACS, bleeding complications are more frequent and outcomes appear worse in individuals treated with UFH compared with LMWH. Combination therapy with LMWH and GP IIb/IIIa inhibitors appears to be better tolerated than with UFH and GP IIb/IIIa inhibitors.</p>
dc.identifier.submissionpathcor_grace/63
dc.contributor.departmentCenter for Outcomes Research
dc.source.pages2285-93


This item appears in the following Collection(s)

Show simple item record